Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples